Comparison of the Impact of 68Ga-DOTATATE and 18F-FDG PET/CT on Clinical Management in Patients with Neuroendocrine Tumors

Article Figures & Data

Download figure
Open in new tab
Download powerpoint
FIGURE 1.
Correlation between mean Ki-67 of NETs and PET/CT tracer results on which clinical management decision was based.
Download figure
Open in new tab
Download powerpoint
FIGURE 2.
Survival curves for patients with bone metastasis (red) vs. soft-tissue metastasis (green) or no metastasis (blue) detected using ⁶⁸Ga-DOTATATE.
Download figure
Open in new tab
Download powerpoint
FIGURE 3.
Survival curves for patients with bone metastasis (red) vs. soft-tissue metastasis (green) or no metastasis (blue) detected using ¹⁸F-FDG.

TABLE 1

Clinical and Epidemiologic Characteristics of the Patients

TABLE 2

Treatment Before ¹⁸F-FDG and ⁶⁸Ga-DOTATATE PET/CT

Treatment	n
Surgery	21 (20.2%)
Active surveillance	20 (19.2%)
Long-acting SSA	13 (12.5%)
None	12 (11.5%)
CMT	11 (10.6%)
Surgery, CMT	10 (9.6%)
Further diagnostic procedure	5 (4.8%)
Surgery, interferon	4 (3.8%)
Surgery, ⁹⁰Y, SSA	4 (3.8%)
PRRT	1 (1.0%)
Surgery, CMT, SSA, TACE, LDT	1 (1.0%)
Surgery, radiofrequency ablation	1 (1.0%)
LDT	1 (1.0%)

SSA = somatostatin analogs; CMT = chemotherapy; ⁹⁰Y = ⁹⁰Y-DOTATATE therapy; TACE = transcatheter arterial chemoembolization; LDT = liver-directed therapy.

TABLE 3

Management Based on ¹⁸F-FDG and ⁶⁸Ga-DOTATATE PET/CT Findings

	Findings on which management was based
Management	⁶⁸Ga-DOTATATE	¹⁸F-FDG	Both	Total
Active surveillance	5	4	22	31 (29.8%)
Chemotherapy	8	10	2	20 (19.2%)
Chemotherapy, TACE	0	0	1	1 (1%)
Everolimus	1	0	0	1 (1%)
Interferon	0	0	2	2 (1.9%)
PRRT	14	0	1	15 (14.4%)
Radiofrequency ablation	0	1	0	1 (1%)
Somatostatin analogs	11	2	2	15 (14.4%)
Surgery	9	5	2	16 (15.4%)
Liver-directed therapy	2	0	0	2 (1.9%)
Total	50	22	32	104